Evidence map›Paper›PMID 41179711›Full record

ArticleWorld journal of hepatology2025

Olga V Smirnova, Aleksander A Sinyakov, Edward V Kasparov

Abstract readEditorial
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Olga V SmirnovaLaboratory of Clinical Pathophysiology, Federal Research Center "Krasnoyarsk Scientific Center of the Siberian Branch of the Russian Academy of Sciences", Separate Subdivision Research Institute for Medical Problems of the North, Krasnoyarsk 660022, Russia. ovsmirnova71@mail.ru.
Aleksander A SinyakovLaboratory of Clinical Pathophysiology, Federal Research Center "Krasnoyarsk Scientific Center of the Siberian Branch of the Russian Academy of Sciences", Separate Subdivision Research Institute for Medical Problems of the North, Krasnoyarsk 660022, Russia.
Edward V KasparovLaboratory of Clinical Pathophysiology, Federal Research Center "Krasnoyarsk Scientific Center of the Siberian Branch of the Russian Academy of Sciences", Separate Subdivision Research Institute for Medical Problems of the North, Krasnoyarsk 660022, Russia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The problem of metabolic dysfunction-associated steatotic liver disease (MASLD) is becoming a non-infectious pandemic, the growth drivers of which are obesity and diabetes mellitus. According to modern concepts, MASLD develops and progresses as a result of the interaction of multiple genetic, environmental and adaptive factors, which include specific genetic polymorphisms (for example, the patatin-like phospholipase domain-containing protein 3 gene) and epigenetic modifications, dietary patterns (for example, high consumption of saturated fats and fructose), physical inactivity, obesity, insulin resistance, dysregulation of adipokine production, lipotoxicity, oxidative stress, intestinal microbiota dysbiosis (small intestinal bacterial overgrowth syndrome). In addition, due to the high infection rate of

Indexed as

Blood glucoseCytokinesHelicobacter pylori infectionLipid profileMetabolic dysfunction-associated steatotic liver diseaseObesity

Identifiers

PMID41179711
PMCPMC12576744

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.